Compare GOOS & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOOS | LXRX |
|---|---|---|
| Founded | 1957 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 931.6M | 1.0B |
| IPO Year | 2016 | 2000 |
| Metric | GOOS | LXRX |
|---|---|---|
| Price | $8.22 | $2.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $12.60 | $4.15 |
| AVG Volume (30 Days) | 719.9K | ★ 2.6M |
| Earning Date | 05-20-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $12.21 | N/A |
| Revenue Next Year | $5.16 | N/A |
| P/E Ratio | $75.22 | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $8.05 | $1.05 |
| 52 Week High | $14.69 | $2.68 |
| Indicator | GOOS | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 46.87 |
| Support Level | $8.05 | $2.17 |
| Resistance Level | $10.42 | $2.49 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 19.05 | 27.87 |
Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale; Direct to Consumer (DTC), and Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of retailers and international distributors, who are partners that have exclusive rights to an entire market, and travel retail locations. Geographically, it has a presence in Canada, the United States, North America, Greater China, Asia-Pacific, and Europe, the Middle East, and Africa.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.